Valuation: Alamar Biosciences, Inc.

Market Cap 2.13B 1.9B 1.76B 1.59B 2.98B 202B 3.03B 21.14B 8.37B 106B 7.99B 7.82B 334B P/E 2026 *
-25.2x
P/E 2027 * -44.4x
Enterprise Value 2.04B 1.82B 1.68B 1.53B 2.85B 194B 2.9B 20.26B 8.02B 101B 7.66B 7.5B 320B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 12.5x
Free-Float
77.76%
Yield 2026 *
-
Yield 2027 * -
1 day+3.26%
1 week+21.40%
Current month-9.92%
1 month-4.51%
3 months+18.54%
6 months+26.45%
1 week 25.28
Extreme 25.275
31.51
1 month 22.98
Extreme 22.98
39.61
Current year 18.84
Extreme 18.845
39.61
1 year 18.84
Extreme 18.845
39.61
3 years 18.84
Extreme 18.845
39.61
5 years 18.84
Extreme 18.845
39.61
10 years 18.84
Extreme 18.845
39.61
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 31/12/2020
Chief Operating Officer 63 31/07/2018
Chief Executive Officer 62 30/06/2018
Director TitleAgeSince
Chairman 62 30/06/2018
Director/Board Member 64 30/04/2020
Director/Board Member 66 27/08/2026
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Free

General Counsel

114,000 0.1643%
01/09/26 Free

Director

31,285 0.0451%
20/04/26 Others

Director

206,781 --
Change 5-day change 1-year change 3-year change Capi.($)
+3.26%+21.40% - - 2.13B
-0.40%-2.34%+17.82%+45.91% 249B
+0.33%+0.64%+3.49%+12.96% 162B
+1.90%+6.00%-17.96%+65.92% 157B
-0.70%+2.93%-55.38%-8.86% 66.22B
+0.15%+4.09%+10.82%+65.55% 52.3B
+0.24%+0.99%-15.19%-10.88% 52.18B
-1.13%+2.85%+16.39%+28.99% 51.34B
-0.47%+0.06%+17.37%+58.29% 48.79B
-0.42%+3.83%+27.55%+77.45% 44.57B
Average +0.28%+4.18%+0.54%+37.26% 88.56B
Weighted average by Cap. +0.15%+1.55%+1.37%+38.41%

Financials

2026 *2027 *
Net sales 119M 106M 97.82M 88.65M 166M 11.26B 169M 1.18B 466M 5.9B 445M 436M 18.59B 166M 148M 137M 124M 232M 15.73B 236M 1.65B 651M 8.24B 622M 609M 25.98B
Net income -64.93M -57.98M -53.56M -48.54M -90.81M -6.16B -92.31M -645M -255M -3.23B -244M -238M -10.18B -49.81M -44.48M -41.09M -37.24M -69.66M -4.73B -70.81M -494M -196M -2.48B -187M -183M -7.81B
Net Debt -89.09M -79.56M -73.5M -66.6M -125M -8.46B -127M -884M -350M -4.43B -334M -327M -13.97B -57.53M -51.37M -47.46M -43.01M -80.46M -5.46B -81.79M -571M -226M -2.86B -216M -211M -9.02B
Projected Income Statement - Annual - Alamar Biosciences, Inc.
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
286
Date Price Change Volume
23/10/26 US$30.69 +3.26% 748,226
22/10/26 US$29.72 -5.50% 675,413
21/10/26 US$31.45 +11.68% 1,141,323
20/10/26 US$28.16 +7.07% 681,634
19/10/26 US$26.30 +4.03% 550,688
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
30.69USD
Average target price
35.40USD
Spread / Average Target
+15.35%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alamar Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. ALMR Stock